Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 118, Issue 4, Pages 1380-1389Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI33125
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA124763, R21 CA118265, CA118265, CA 124763] Funding Source: Medline
Ask authors/readers for more resources
Mobilization of endothelial progenitor cells (EPCs) from the bone marrow and their subsequent participation in neovessel formation are implicated in tumor growth and neovascularization. As the neurotransmitter dopamine (DA) modulates adult endothelial cell function, we hypothesized that DA might have a regulatory role in mobilization of EPCs from the bone marrow niche. We show that there was a significant decrease in bone marrow DA content and an increase in EPC mobilization in tumor-bearing mice associated with tumor neovascularization. DA treatment of tumor-bearing mice inhibited EPC mobilization and tumor growth through its D-2 receptors, as DA treatment failed to inhibit EPC mobilization in tumor-bearing mice treated with a specific DA D-2 receptor antagonist and in tumor-bearing mice lacking the D-2 receptor. In addition, we found that DA, through D-2 receptors, exerted its inhibitory effect on EPC mobilization through suppression of VEGFA-induced ERK1/ERK2 phosphorylation and MMP-9 synthesis. These findings reveal a new link between DA and EPC mobilization and suggest a novel use for DA and D-2 agents in the treatment of cancer and other diseases involving neovessel formation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available